The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets

American Journal of Hematology

Volumn 82, Issue 11, 2007, Pages 986-995

  Karmohapatra, Soumendra K ^a   Chakraborty, Kushal ^a   Kahn, Nighat N ^b   Sinha, Asru K ^a,b  

^a Sinha Institute of Medical Science and Technology   (India)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIETHYLAMINOETHANOL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APROTININ; CELLULOSE; CYCLIC GMP; ENZYME PRECURSOR; FIBRIN DEGRADATION PRODUCT; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLASMIN; POLYPEPTIDE; PROSTAGLANDIN SYNTHASE; SEPHADEX; SERINE PROTEINASE; TRITON X 100;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CALCIFICATION; CHROMATOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NORMAL HUMAN; PRIORITY JOURNAL; PURIFICATION; SOLUBILIZATION; SYNTHESIS; THROMBOCYTE; THROMBOCYTE RICH PLASMA; THROMBUS;

ADULT; AGED; ASPIRIN; BLOOD PLATELETS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLASMIN; THROMBOSIS;

EID: 35548980490     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20955     Document Type: Article

References (40)

1. Steering committee of the physicians health study research group: Final report on the aspirin component of the aspirin component of the on going physicians health study. N Engl J Med 1989;321:129-135.
2. Rojers WJ, Bowldy LJ. Treatment of myocardial infarction in the United States (1990-1993). Observations from the National Registry of Myocardial Infarction. Circ Res 1994;90:2103-2114.
3. Shtivelband MI, Juneja HS, Lee S, Wu KK. Aspirin and salicylate inhibit colon cancer medium- and VEGF- induced endothelial tube formation: Correlation with suppression of cyclooxygenase-2 expressions. J Thromb Haemost 2003;1:2225-2233.
4. Robert JM. Gastrointestinal Tract Cancer: Harrison's Principle of Internal medicine. New York: McGraw-Hill; 1998. pp 568-578.
5. Hack N, Carey F, Crawford N. The inhibition of platelet cyclo-oxygenase by aspirin is associated with the acetylation of a 72kDa polypeptide in the intracellular membranes. Biochem J 1984;223:105-111.
6. Kalgutkar AS, Crews BC, Rowlison SW, Garner C, Seibert K, Marnett LJ. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998;280:1268-1270.
7. Falk E. Dynamics in thrombus formation. Ann NY Acad Sci 1992;667:204-23.
8. Fuster V, Badimon J, Chesebro JH, Fallon JT. Plaque rupture, Thrombosis, and therapeutic implications. Haemostasis 1996;26:269-284.
9. Antman EM, Braunwald E. Acute Myocardial Infarction: Harrison's Principle of Internal Medicine. New York: McGraw-Hill; 1998. pp 1352-1365.
10. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003;14:421-427.
11. Kanowitz PJ. Evidence for the inhibitory role of guanosine 3, 5,-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981;57:946-955.
12. Sinha AK, Acharya K, Bhattacharya S, Mazumder S, Bauman WA, Kahn NN. Prevention of thrombosis in vivo by nitric oxide. Ind J Physiol Allied Sci 1998;52:148-161.
13. Murad F, Forstermann U, Nakane M, Schmidt H, Pollock J, Sheng H, Matsumoto T, Warner T, Mitchell J, Tracey R. The nitric oxide-cyclic GMP signal transduction pathway in vascular smooth muscle preparations and other tissues. Jpn J Pharmacol 1992;58:150P-157P.
14. Haskel EJ, Eisenberg PR, Abendschein DR. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood. Blood Coagul Fibrinolysis 1993;4:7-13.
15. Jia L, Bonaventura C, Bonaventura J, Stamler SJ. S-nitrosohaemoglobin: A dynamic activity of blood involved in vascular control. Nature 1996;380:221-226.
16. Cox RD, Frank CW. Determination of nitrate and nitrite in blood and urine by Chemiluminiscence. J Anal Toxicol 1982;6:148-152.
17. 1/ prostacyclin receptor of human blood platelets. J Biol Chem 1987;262:12685-12691.
18. 4. Nature 1970;27:680-685.
19. Robbins KC, Summaria L. Human plasminogen and plasmin. Methods Enzymol 1970;19:184-199.
20. Remmert LF, Cohen PP. Partial purification and properties of a proteolytic enzyme of human serum. J Biol Chem 1949;181:431-448.
21. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement by the folin-phenol reagent. J Biol Chem 1951;1193:265-275.
22. Carr ME Jr, Alving BM. Effect of fibrin structure on plasmin mediated dissolution of plasma clot. Blood Coagul Fibrinolysis 1995;6:567-573.
23. Raser KJ, Posner A, Wang KK. Casein zymography: A method to study μ-calpain and their inhibitory agents. Arch Biochem Biophys 1995;319:211-216.
24. Deutscher MP. Maintaining protein stability. Methods Enzymol 1990;182:83-89.
25. Rimon A, Shamash Y, Shapiro B. The plasmin inhibitor of human plasma IV: Its action on plasmin, trypsin, chymotrypsin and thrombin. J Biol Chem 1966;241:5102-5107.
26. Trovati M, Anfossi G, Massuco P, et al. Insulin stimulates nitric oxide synthesis in human platelets and through nitric oxide increases platelet concentrations of both guanosine 3,5-monophosphate and adenosine 3,5-cyclic monophosphate. Diabetes 1997;46:742-749.
27. Kahn NN, Acharya K, Bhattacharya S, et al. Nitric oxide: The "second messenger" of insulin. IUBMB Life 2000;49:441-450.
28. Lorenzo Fernandez P, Mediavilla A, Moreno A, Castrillo M, Lorenzo-Velazquez B. Pharmacological aspects of sodium nitroprusside. Arch Inst Farmacol Exp (Madr) 1971;23:1-51.
29. Summaria L, Hsieth B, Groskop WR, Robbins KC. The isolation and characterization of the S-carboxymethyl β (light) chain derivative of human plasmin. J Biol Chem 1967;242:5046-5052.
30. Robbins KC, Summaria L, Hsieth B, Shah RJ. The peptide chains of the human plasmin. J Biol Chem 1967;242:2333-2342.
31. Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985;206:4303-4311.
32. Park S, Harker L, Marzec VM, Levin EG. Determination of single chain type plasminogen activator in platelet membrane. Blood 1989;73:1421-1425.
33. Angles-Cano E. Overview on fibrinolysis: Plasminogen activation pathways on fibrin and cell surface. Chem Phys Lipids 1994;67:353-362.
34. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990;30:535-560.
35. Kahn NN, Bauman WA, Sinha AK. Insulin-induced release of plasminogen activator from human blood platelets. Am J Physiol 1995;268:H117-H124.
36. Yao SK, Akhtar S, Scott-Burden T, et al. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Circulation 1995;92:1005-1010.
37. Sinha AK, Bhattacharya S, Acharya K, Mazumder S. Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosis in vivo. Life Sci 1999;65:2687-2696.
38. Wouters MA, Lau KK, Hogg PJ. Cross-strand disulphide in cell entry proteins: Poised to act. Bioassay 2003;26:73-79.
39. Bjornsson TD, Schneider DE, Berger H Jr. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989;250:154-161.
40. Buczko W, Mogielnicki A, Kramkowski K, Chabielska E. Aspirin and the fibrinolytic response. Thromb Res 2003;110:331-334.